All News

Shingrix can be give to inflammatory arthritis pts? Collective report from the Brigham & Women’s Hospital looked at the safety of Shingrix given to 300 RA, PsA, etc patient without any reports of H.Zoster and a 4% rate of "flares". #EULAR2019 FRI0068 https://t.co/Wkx5V9vM8r https://t.co/kErMMU97tB

Links:

Dr. John Cush RheumNow ( View Tweet)
What’s next in biosimilars? Visit RheumNow to listen to experts discuss this and more in "Therapeutic Update: Biosimilars in Rheumatology," a video series sponsored by Sandoz, Inc. https://t.co/1vmnEJqOSi #sponsored #biosimilars

Links:

Dr. John Cush RheumNow ( View Tweet)

Very interesting. Another strike against steroids...? https://t.co/LGz7fKh9hU

Links:

Paul Sufka, MD psufka ( View Tweet)

Updated treatment algorithm for extrarenal #Lupus 👉🏻 MSK 👉🏻 Skin 👉🏻 Hematological 👉🏻 Cardiovascular 👉🏻 Lung 👉🏻Serositis 👉🏻 Vasculitis #EULAR2019 https://t.co/LDr0hKZAfV
Juan Ovalles, MD, PhD DrJuanOvalles ( View Tweet)
JAK system really important for many bodily functions. So the aim is to “turn down the thermostat” without “turning it off” Ernest Choy #EULAR2019 https://t.co/863ktP3CIg
Dr Irwin Lim _connectedcare ( View Tweet)
#EULAR2019 session ‘Getting A Grip on The Comorbidities in Gout’ focused on the complex and variable disease profile patients experience and clinicians treat. Do #gout co-morbidities occur in patterns? Dr Ed Roddy discusses. Abstract SP0061 @RheumNow https://t.co/EHoNdP7iMo
Gout Study Group GoutGroup ( View Tweet)
Baracitinib affects JAK2 more than Tofacitinib. Difference can be seen with lower Hb & higher platelets #EULAR2019 https://t.co/BfzuyZI8f9
Dr Irwin Lim _connectedcare ( View Tweet)
JAKi also helps reduce bone loss #EULAR2019 https://t.co/8JOUp3aJWQ
Dr Irwin Lim _connectedcare ( View Tweet)
This graph is a reminder that over time, the level of Inflammation in RA may reduce with lower symptoms. However, CUMULATIVE inflam leads to increasing damage & disability #EULAR2019 https://t.co/ujhODMOp4E
Dr Irwin Lim _connectedcare ( View Tweet)
Look at the difference in patient reported outcome measures. Baracitinib vs Adalimumab #EULAR2019 https://t.co/xrQDdKIspV
Dr Irwin Lim _connectedcare ( View Tweet)
Risk factors for #sarcopenia in #rheumatoid arthritis 👉🏼Male 👉🏼Old age 👉🏼Glucocorticoid 👉🏼Increased MMP3 👉🏼Increased HAQ #EULAR2019 THU0159 #muscle #RheumatoidArthritis https://t.co/Fn1SvCapqm
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
patients are lucky to have docs like @DrHillaryNorton sharing these #arthritis #breakthroughs #EULAR2019 https://t.co/nQg1WIFD4c

Links:

CreakyJoints.org CreakyJoints ( View Tweet)

Optimizing ➡️#weight ➡️sleep ➡️physical #health ➡️emotional health ➡️MTX use 👉🏼may improve persistent #fatigue beyond control of #rheumatoid inflammation via @Susanbartlett12 #EULAR2019 #obesity https://t.co/vuMNWazloo
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
TNF inhibitors vs JAK inhibitors: what’s the head-to-head study state of play? (**efficacy not safety, non-real life data of course) #EULAR2019 Gerd Burmester on ‘The wind of change in RA’ @RheumNow https://t.co/zK1wqskmLc
David Liew drdavidliew ( View Tweet)
AE in SENCIS data. #EULAR2019 Ofev had higher discontinuation due to medication and higher GI associated illness in the trial. https://t.co/0E21Z4B8TU
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
MAXIMISE: rct of secukinumab on axial manifestations of PsA #EULAR2019 Positive as we would expect https://t.co/I1GfxlfWuX
Dr Irwin Lim _connectedcare ( View Tweet)
Burmester on combining TNFi and JAK inhibitors in RA: “I have approached... even companies with both a TNF inhibitor and a JAK inhibitor. I have failed”. Wouldn’t it be interesting to see some data on this? #EULAR2019 @RheumNow

David Liew drdavidliew ( View Tweet)

Solid tumors outcomes in patients with RA treated with #Abatacept - no increase in risk 5.2k in patients over 10years Dra. Teresa Simon #EULAR2019 https://t.co/BIA90SH7qc
Dr.Martínez MtzReuma ( View Tweet)
I am also a big fan of BPs for their durability of treatment effect https://t.co/DKNYboSjdA

Links:

Dr Philip Robinson philipcrobinson ( View Tweet)

Gerd Burmester raising some interesting practical questions regarding the use of #biosimilars at #EULAR2019: How many drugs can a rheumatologist memorize? How much information material et.c can a rheumatologist store? How to avoid the ‘#nocebo’ effect when switching?

NatRevRheumatol NatRevRheumatol ( View Tweet)

×